Loading clinical trials...
Loading clinical trials...
A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC
Conditions
Interventions
Efgartigimod PH20 SC
Locations
13
United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
Neurology Associates PA
Maitland, Florida, United States
Visionary Investigators Network
Miami, Florida, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
Velocity Clinical Research
Lafayette, Louisiana, United States
SRI International - ClinEdge
Plymouth, Michigan, United States
Start Date
December 10, 2024
Primary Completion Date
February 19, 2026
Completion Date
February 19, 2026
Last Updated
April 6, 2026
NCT06290141
NCT06858579
NCT06752356
NCT06920004
NCT07027111
NCT07121985
Lead Sponsor
argenx
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions